February 28, 2022 10:45 AM EST

Safety concerns cause GSK to stop highly anticipated vaccine trial in surprise setback

Amber Tong

Days after putting a trio of vaccine trials on voluntary pause, GlaxoSmithKline is officially stopping enrollment and vaccination in trials involving …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Safety concerns cause GSK to stop highly anticipated vaccine trial in surprise setback

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CDER Director Patrizia Cavazzoni to step down ahead of Trump presidency

Intellia to cut workforce by 27%, plans commercialization of first CRISPR therapy in 2027

Lilly ventures into pulmonary fibrosis with startup Mediar

John Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet; Amylyx names commercial chief

Exclusive: Moderna's former top scientist has a new startup using AI to improve mRNA therapies

Four biotechs emerge with $800M and in-licensed assets on Friday

Safe­ty con­cerns cause GSK to stop high­ly an­tic­i­pat­ed vac­cine tri­al in sur­prise set­back

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Safety concerns cause GSK to stop highly anticipated vaccine trial in surprise setback